Last year, FDA approved Medtronic plc (MDT)’s innovative pacemaker. It believes the new solution will become a vital growth force soon.
Among the pacemaker market leaders for several years now, Medtronic is one of the most prominent companies on the market. Despite having a successful program to date, in early 2020, this company won the approval to sell the Micra AV, the world’s smallest Atrioventricular Synchronized Pacemaker. Patients with AV block usually find the AV device beneficial, because it improves the coordination between the atrium and the ventricle. The device received regulatory approval from the European Union in 2020, and in December that same year, the device was tested in Canada.
Micra AV pacemakers can be readily adopted by many patients. Patients who are newly diagnosed and those who need pacemakers replaced due to resource exhaustion are the subjects of our discussion. Batteries in conventional devices typically last between five and fifteen years and require surgery to replace them. Besides having a battery, the Micra also has a removable battery, which makes it easier for patients to replace a device.
Advances in medicine and life expectancy are making pacemakers a necessity in almost every part of the world. The installation of pacemakers has saved hundreds of thousands of lives and improved the quality of life for millions of patients. In 2016, there were 1.14 million pacemakers in use worldwide, according to Statista. More than 25 % of these dollars will be generated by the year 2023. The pacemaker market is expected to grow at an annual rate of 4.3% to $7.5 billion through 2027.
Competitive pressures are at risk for Medtronic because major medical device manufacturers such as EBR Systems, Abbott Laboratories, and Boston Scientific are also developing innovative pacemaker options. Although Medtronic thinks that its leadership is solid at this stage, it provided specific information about Micra sales: sales rose 64 % globally, and 76 % domestically. Based on the estimated 15 to 55 % growth in pacemaker sales for the Micra AV, Medtronic anticipates sales of the device to grow.
Medtronic plc (MDT) is trading at around $125.91, meaning its value has shot up 43.6% since its 52-week low. Intraday trading for MDT stock has produced highs of $126.83 and lows of $125.075. Shares of the MDT stock have touched highs of $126.14 and lows of $87.68 over the last 52 weeks, with a recent intraday change of 0.05%.